The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)

9 Jan 2020 10:04

Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN) 09-Jan-2020 / 10:03 GMT/BST


 

London, UK, 9 January 2020

Edison issues initiation on Silence Therapeutics (SLN)

We are initiating coverage of Silence Therapeutics (SLN), a developer of siRNA drugs for diseases that can be genetically targeted. Silence has a proprietary platform for developing siRNA therapeutics, the strength of which was highlighted by preclinical development deals with Mallinckrodt and Takeda (details below). The company will also be re-entering the clinic in Q120 with SLN124, its own drug for iron overload. We are initiating with a valuation of £345m or 440p per share.

 

Our initial valuation of £345m or 440p per share is based on a risk-adjusted NPV analysis of the firm's assets and revenue streams and is driven primarily by our valuation of SLN124 (£141m). We forecast that it will require £105m in additional capital to reach profitability in 2026, offset by potential business development deals.

Click here to view the full report.

 

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway, +1 646 653 7036

healthcare@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

949913 09-Jan-2020 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
30th Mar 20167:00 amRNSHolding(s) in Company
22nd Mar 20167:00 amRNSNotice of Results
18th Jan 20167:00 amRNSBoard changes
12th Nov 20157:00 amRNSBoard appointment
30th Oct 20152:32 pmRNSLicensee's drug to commence Ph 2/Ph 3 trials
29th Sep 20157:00 amRNSInterim Results
22nd Sep 20157:19 amRNSBoard Change and Notice of Results
30th Jul 20157:01 amRNSInterim Board Change
1st Jun 201511:42 amRNSResult of AGM
1st Jun 20157:00 amRNSAGM statement and clinical trial interim analysis
14th May 20159:55 amRNSReplacement: Holding(s) in Company
14th May 20157:00 amRNSClinical trial update
12th May 201510:19 amRNSHolding(s) in Company
11th May 20155:31 pmRNSHolding(s) in Company
11th May 20153:07 pmRNSHolding(s) in Company
11th May 20153:07 pmRNSHolding(s) in Company
11th May 201511:29 amRNSHolding(s) in Company
11th May 201510:50 amRNSHolding(s) in Company
11th May 201510:06 amRNSNotice of AGM
8th May 20155:21 pmRNSHolding(s) in Company
1st May 201510:32 amRNSResult of General Meeting and Additional Listing
16th Apr 20155:48 pmRNSAdditional Listing
8th Apr 201511:33 amRNSFundraising update
2nd Apr 20152:34 pmRNSPreliminary results
2nd Apr 20152:34 pmRNSConditional fundraising of approximately £40m
23rd Mar 20157:00 amRNSClinical trial update
16th Feb 20157:00 amRNSPresentation at RNA Therapeutics conference
12th Feb 20157:00 amRNSSuccessful European patent appeal
27th Jan 20157:00 amRNSGrant of share options
5th Jan 20157:00 amRNSBoard Changes
15th Dec 20147:00 amRNSBoard appointment
1st Dec 20147:00 amRNSTrading update and capital markets presentation
1st Dec 20147:00 amRNSTechnology breakthrough
18th Nov 20147:00 amRNSPublication of study data
3rd Nov 201410:26 amRNSAdditional Listing
22nd Oct 20145:44 pmRNSNotification of Major Interest in Shares
23rd Sep 201411:41 amRNSAdditional Listing
16th Sep 20147:00 amRNSHalf year results
2nd Sep 20149:05 amRNSBoard change
27th Aug 20143:38 pmRNSNotice of Results
5th Aug 20147:00 amRNSPublication of pre-clinical study data
30th Jul 20147:00 amRNSLicensee confirms favourable trial outcome
18th Jul 20144:40 pmRNSSecond Price Monitoring Extn
18th Jul 20144:35 pmRNSPrice Monitoring Extension
17th Jul 20145:01 pmRNSNotification of major interest in shares
16th Jul 20147:00 amRNSCompletion of recruitment for phase 2a trial
9th Jul 20144:40 pmRNSSecond Price Monitoring Extn
9th Jul 20144:35 pmRNSPrice Monitoring Extension
3rd Jul 20144:35 pmRNSPrice Monitoring Extension
27th Jun 20144:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.